BG
CORT icon

Bellevue Group’s Corcept Therapeutics CORT Stock Holding History

Bellevue Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,495
Closed -$365K – 167
2025
Q4 		$365K Buy
10,495
+9,268
+755% +$728K 0.01% 142
2025
Q3 		$102K Buy
+1,227
New +$88.8K ﹤0.01% 142

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bellevue Group's CORT Position: Q1 2026 in Review

Bellevue Group sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 10,495 shares — an estimated $365K sold.

Bellevue Group first reported a position in CORT in Q3 2025 and held it in 2 quarters. The position peaked at $365K in Q4 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Bellevue Group reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 10,495 Corcept Therapeutics shares in Q1 2026, an estimated $365K.
  • Bellevue Group first reported a position in Corcept Therapeutics in Q3 2025 and held it in 2 quarters.
  • Bellevue Group's Corcept Therapeutics position peaked at $365K in Q4 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.